Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Abetz L, Barghout V, Arbuckle R, Bosch V, Shirina N, Saad F (2006) Impact of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases in a randomised placebocontrol trial. J Clin Oncol.
http://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.4638
2. Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC et al (2017) Bone health and bonetargeted therapies for prostate cancer: a programme in evidence-based care—cancer care ontario clinical practice guideline. Clin Oncol 29(6):348–355
3. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N et al (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31(5):578–583
4. Coleman R, Gnant M, Morgan G, Clezardin P (2012) Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 104(14):1059–1067
5. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(8 Suppl):1588–1594